Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Experimental cancer drugs
Sitravatinib
Другие языки:

    Sitravatinib

    Подписчиков: 0, рейтинг: 0
    Sitravatinib
    Sitravatinib.svg
    Identifiers
    • N-(3-Fluoro-4-{[2-(5-{[(2-methoxyethyl)amino]methyl}-2-pyridinyl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)-N′-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide
    CAS Number
    ChemSpider
    UNII
    KEGG
    Chemical and physical data
    Formula C33H29F2N5O4S
    Molar mass 629.68 g·mol−1
    3D model (JSmol)
    • COCCNCc1ccc(nc1)c2cc3c(s2)c(ccn3)Oc4ccc(cc4F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F
    • InChI=1S/C33H29F2N5O4S/c1-43-15-14-36-18-20-2-8-25(38-19-20)29-17-26-30(45-29)28(10-13-37-26)44-27-9-7-23(16-24(27)35)40-32(42)33(11-12-33)31(41)39-22-5-3-21(34)4-6-22/h2-10,13,16-17,19,36H,11-12,14-15,18H2,1H3,(H,39,41)(H,40,42)
    • Key:WLAVZAAODLTUSW-UHFFFAOYSA-N

    Sitravatinib (MGCD516) is an experimental drug for the treatment of cancer. It is a small molecule inhibitor of multiple tyrosine kinases.

    Sitravatinib is being developed by Mirati Therapeutics.

    Ongoing phase II trials include a trial for liposcarcoma, a combination trial for non-small cell lung cancer, and a combination trial with nivolumab for renal cell carcinoma. Sitravatinib is being evaluated in ongoing trials in patients with advanced non-small cell lung cancer, including in a combination trial with nivolumab in those who are resistant to checkpoint inhibitor therapy, and certain patients who are naïve to checkpoint inhibitor therapy.


    Новое сообщение